Ivabradine Ingen Pharma (Ivabradine Oxalate)

Ivabradine acts on the cardiac If current to control heart rate in cardiovascular disease.

• Chronic stable angina pectoris: reduces the frequency of angina attacks by lowering heart rate.
• Chronic heart failure (reduced ejection fraction) with elevated heart rate: improves outcomes by decreasing myocardial oxygen demand.
• Patients with coronary artery disease who cannot tolerate beta‑blockers: provides heart‑rate control as an alternative therapy.

• Ivabradine selectively inhibits the funny (If) current in the sino‑atrial node, which slows the spontaneous depolarisation of pacemaker cells. This reduction in the If current decreases heart rate without affecting myocardial contractility, ventricular repolarisation, or blood pressure, allowing a targeted heart‑rate lowering effect in patients with angina or heart failure.

Adverse reactions may occur with ivabradine therapy.

Common Side Effects

• Bradycardia: resting heart rate may fall below expected levels.
• Luminous phenomena (phosphenes): transient visual sensations of bright spots.
• Headache: mild to moderate intensity.
• Dizziness or vertigo: especially on standing.
• Fatigue: general feeling of tiredness.
• Blurred vision: temporary visual disturbances.

Serious or Rare Side Effects

• Symptomatic bradycardia requiring medical intervention.
• Atrial fibrillation or other serious arrhythmias.
• Severe hypotension leading to syncope.
• Allergic reactions such as rash, pruritus, or angioedema.
• Visual disturbances persisting beyond transient phosphenes.

Before prescribing ivabradine, clinicians should consider several safety measures.

• Assess baseline heart rate: ensure resting HR ≥ 60 bpm before initiation.
• Monitor for bradycardia: discontinue if HR falls below 50 bpm or symptomatic.
• Avoid in severe hepatic impairment: contraindicated due to altered metabolism.
• Caution with concomitant CYP3A4 inhibitors: dose adjustment or avoidance may be required.
• Store at ambient temperature: keep in the original container, protect from moisture and light.

Ivabradine may interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase ivabradine plasma levels.
• Co‑administration with other heart‑rate lowering agents (beta‑blockers, digoxin): risk of excessive bradycardia.
• Verapamil (CYP3A4 inhibitor): may markedly raise ivabradine concentrations.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inhibitors (e.g., diltiazem): may require dose adjustment.
• Drugs that prolong the QT interval (e.g., certain antiarrhythmics): monitor ECG for additive effects.
• Smoking: induces CYP3A4 and may reduce ivabradine efficacy.